ERBB2 and neoplasm: Persistent YES1 activation promotes tumor growth despite HER2 inhibition, and targeting YES1 with Src inhibitors such as dasatinib has restored T-DM1 sensitivity in preclinical models, suggesting a potential therapeutic avenue [132].